Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer
(2024) In European Urology Oncology 7(3). p.344-354- Abstract
CONTEXT: Prostate cancer is a molecularly heterogeneous disease that is amenable to diagnostic testing to identify patients potentially eligible for personalised treatments inform familial risk and provide relevant information about potential prognosis. Several guidelines support the integration of genomic testing in a shared decision-making framework so that both health care professionals (HCPs) and patients are involved in determining the best treatment approach. OBJECTIVE: To review current guidelines on molecular diagnostic testing for homologous recombination repair (HRR) gene alterations in patients with metastatic prostate cancer, with the aim of providing practical considerations for effective guideline implementation and... (More)
CONTEXT: Prostate cancer is a molecularly heterogeneous disease that is amenable to diagnostic testing to identify patients potentially eligible for personalised treatments inform familial risk and provide relevant information about potential prognosis. Several guidelines support the integration of genomic testing in a shared decision-making framework so that both health care professionals (HCPs) and patients are involved in determining the best treatment approach. OBJECTIVE: To review current guidelines on molecular diagnostic testing for homologous recombination repair (HRR) gene alterations in patients with metastatic prostate cancer, with the aim of providing practical considerations for effective guideline implementation and establishment of an appropriate pathway for molecular diagnostic testing. EVIDENCE ACQUISITION: We undertook a nonsystematic narrative review of the literature using PubMed to identify current guidelines and recommendations on molecular diagnostic testing for BRCA and/or homologous recombination repair gene alterations (HRRm) in patients with prostate cancer. In addition, selected articles that included BRCA/HRRm testing in clinical trials in metastatic castration-resistant prostate cancer and real-world evidence were also evaluated. Websites for relevant societies were reviewed for molecular diagnostic guidelines not published on PubMed. EVIDENCE SYNTHESIS: Our review of guidelines published by several international societies that include molecular testing in prostate cancer identified variations in molecular testing approaches. The review of testing approaches used in clinical trials and real-world settings also highlighted several aspects that require improvement. Therefore, we compiled practical guidance for establishing an appropriate BRCA/HRR mutation testing pathway. CONCLUSIONS: While there are several challenges to molecular testing and interpretation of test results that require enhancement, a multidisciplinary team approach will empower HCPs and their institutions to improve on or initiate their own molecular testing pathways. This in turn will lead to improvements in management strategies for patients with metastatic prostate cancer, for whom better treatment outcomes is a significant unmet need. PATIENT SUMMARY: Establishing a molecular testing pathway in clinical practice for patients with metastatic castration-resistant prostate cancer will lead to fairer and more equal access to personalised treatments. This should lead to better outcomes, particularly for patients whose disease has spread to other areas of the body.
(Less)
- author
- Schostak, Martin ; Bradbury, Angela ; Briganti, Alberto ; Gonzalez, David ; Gomella, Leonard ; Mateo, Joaquin ; Penault-Llorca, Frédérique ; Stenzinger, Albrecht ; Wyatt, Alexander W. and Bjartell, Anders LU
- organization
- publishing date
- 2024-06-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Circulating tumour DNA, Metastatic castration-resistant prostate cancer, Molecular diagnostics, Multidisciplinary team, PARP inhibitors, Tumour testing
- in
- European Urology Oncology
- volume
- 7
- issue
- 3
- pages
- 11 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85193650338
- pmid:37714762
- ISSN
- 2588-9311
- DOI
- 10.1016/j.euo.2023.08.004
- language
- English
- LU publication?
- yes
- id
- 620bd8b0-5700-4e54-a147-0a9230ff2dec
- date added to LUP
- 2024-05-31 15:29:58
- date last changed
- 2024-06-14 16:16:12
@article{620bd8b0-5700-4e54-a147-0a9230ff2dec,
abstract = {{<p>CONTEXT: Prostate cancer is a molecularly heterogeneous disease that is amenable to diagnostic testing to identify patients potentially eligible for personalised treatments inform familial risk and provide relevant information about potential prognosis. Several guidelines support the integration of genomic testing in a shared decision-making framework so that both health care professionals (HCPs) and patients are involved in determining the best treatment approach. OBJECTIVE: To review current guidelines on molecular diagnostic testing for homologous recombination repair (HRR) gene alterations in patients with metastatic prostate cancer, with the aim of providing practical considerations for effective guideline implementation and establishment of an appropriate pathway for molecular diagnostic testing. EVIDENCE ACQUISITION: We undertook a nonsystematic narrative review of the literature using PubMed to identify current guidelines and recommendations on molecular diagnostic testing for BRCA and/or homologous recombination repair gene alterations (HRRm) in patients with prostate cancer. In addition, selected articles that included BRCA/HRRm testing in clinical trials in metastatic castration-resistant prostate cancer and real-world evidence were also evaluated. Websites for relevant societies were reviewed for molecular diagnostic guidelines not published on PubMed. EVIDENCE SYNTHESIS: Our review of guidelines published by several international societies that include molecular testing in prostate cancer identified variations in molecular testing approaches. The review of testing approaches used in clinical trials and real-world settings also highlighted several aspects that require improvement. Therefore, we compiled practical guidance for establishing an appropriate BRCA/HRR mutation testing pathway. CONCLUSIONS: While there are several challenges to molecular testing and interpretation of test results that require enhancement, a multidisciplinary team approach will empower HCPs and their institutions to improve on or initiate their own molecular testing pathways. This in turn will lead to improvements in management strategies for patients with metastatic prostate cancer, for whom better treatment outcomes is a significant unmet need. PATIENT SUMMARY: Establishing a molecular testing pathway in clinical practice for patients with metastatic castration-resistant prostate cancer will lead to fairer and more equal access to personalised treatments. This should lead to better outcomes, particularly for patients whose disease has spread to other areas of the body.</p>}},
author = {{Schostak, Martin and Bradbury, Angela and Briganti, Alberto and Gonzalez, David and Gomella, Leonard and Mateo, Joaquin and Penault-Llorca, Frédérique and Stenzinger, Albrecht and Wyatt, Alexander W. and Bjartell, Anders}},
issn = {{2588-9311}},
keywords = {{Circulating tumour DNA; Metastatic castration-resistant prostate cancer; Molecular diagnostics; Multidisciplinary team; PARP inhibitors; Tumour testing}},
language = {{eng}},
month = {{06}},
number = {{3}},
pages = {{344--354}},
publisher = {{Elsevier}},
series = {{European Urology Oncology}},
title = {{Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer}},
url = {{http://dx.doi.org/10.1016/j.euo.2023.08.004}},
doi = {{10.1016/j.euo.2023.08.004}},
volume = {{7}},
year = {{2024}},
}